header logo image


Page 408«..1020..407408409410..420430..»

Animals large and small saved by a rescue network forged by years of Bay Area wildfires – San Francisco Chronicle

August 28th, 2020 2:54 am

Its very quiet right now at Sweet Farm in Half Moon Bay. No chickens clucking, no cows mooing, no goats bleating. In fact, no animals currently live on the 12-acre farm.

On Thursday night, about 35 farm staff and volunteers hauled 175 animals out of the nonprofit sanctuary as the CZU Lightning Complex fires grew.

Sweet Farm owners Nate Salpeter and Anna Sweet had taken in 35 evacuated animals from a sanctuary farther south on Wednesday night. But within 24 hours, the evacuation zone was extended to just the other side of their farms ridgeline. So they jumped into action.

Theres a vast network of sanctuaries and also various animal rescue groups that all come together in moments of crisis, Salpeter said. People really step up when its needed. ... It was a very professional and very coordinated effort.

With the help of the San Mateo County Large Animal Evacuation Group, the animals were shuttled off to sanctuaries a safe distance from the blazes that have engulfed 78,000 acres in San Mateo and Santa Cruz counties. It was the first wildfire evacuation for Sweet Farm, which opened in 2015.

Theirs is just one of many stories of animal evacuation efforts during the recent rash of lightning-caused wildfires that erupted early last week throughout the Bay Area and beyond. From Daly City to UC Davis to Santa Cruz, a network of agencies, animal owners and volunteers is building on practice from previous fire disasters to coordinate care and shelter.

This recent group of fire complexes across 12 counties endangered many farm and ranchlands, forcing owners to act quickly to move animals of all sizes off their properties.

The San Mateo County Large Animal Evacuation Group specializes in these distinctive challenges that are growing more common as wildfire seasons worsen. Organization President Kris Thoren said the early arrival of wildfires this year underscores the need for large-animal owners to have a plan in place before crisis hits.

Large animals need preparation, Thoren said. Its not like throwing a dog in the back of the car. You need to think ahead, be prepared with your emergency plan and practice that emergency plan.

Salpeter was relieved to have help from volunteers who understood how to handle different types of animals, including their 37-year-old stallion.

These animals come from animal abuse situations and are recovering from different types of traumas, he said. Just last year (the stallion) had ocular cancer and had to have one of his eyes removed. In an evacuation situation, there's a lot of noise and things going on. Not being able to see out of the side of his face becomes even more stressful.

The San Mateo group has been a major piece of the evacuation puzzle. Dozens of its volunteers mobilized to assist with coordination and care at the Cow Palace in Daly City, which is housing nearly 300 large animals evacuated from across San Mateo County, most from the south coast.

In five days, the facility has taken in 75 sheep, 68 cattle, 54 goats, 53 chickens, 36 horses, four peacocks, three llamas, one pig and one donkey.

The San Mateo Office of Emergency Services put the Cow Palace on standby Tuesday afternoon, and county officials activated the facility as an emergency evacuation center less than 24 hours later, said Cow Palace CEO Lori Marshall. As part of the state fairground network, the event center was prepared for the logistical challenge of housing a large number of animals on the fly, she said.

We were already making calls to get stalls and setting up the livestock pens to prepare for the animals, Marshall said.

A group of 75 sheep and three truckloads of cattle were just some of the large animals evacuated to the Cow Palace on Sunday evening. Animals that arrive together are kept in the same pen to give them a sense of normalcy among the upheaval. Every day, more animals arrive, Marshall said.

They are evaluated by a veterinarian, and notes are posted outside the pen or stable to ensure that volunteers know the correct food and medicine that each animal requires.

Pumpkin, a 21-year-old golden palomino horse, and an 18-year-old donkey named Trouble were among the first evacuees to show up. Pumpkin and Trouble are being kept together in the stables set up in the Cow Palace parking lot. Pumpkin receives her evening medicine in a slice of apple and twice-daily feedings of her preferred grass hay, in accordance with her owner Steve Grahams wishes.

We are relieved, Graham said by phone Monday. We were very worried, but its good to know that they are safe and in good hands.

In Yolo County, the renowned UC Davis School of Veterinary Medicine also ramped up efforts to help care for animals injured in the LNU Lighting Complex fires. Most are coming from Napa and Solano counties.

Every disaster is different in terms of the types of animals and injuries that we see, said Dr. Bret McNabb, the clinics director. The nature of where the fires have been so far has affected horses and livestock in the area, and its certainly skewing more toward large animal injuries than small at this point.

Since Friday, the clinic has treated four horses, nine alpacas and llamas, two sheep, six goats, and two cats, mostly for burns and smoke inhalation, or secondary complications from wildfires and evacuations. Teams are also deployed in the field at local evacuation centers and with animal control officials behind fire lines to find animals in need of medical attention.

McNabb said while the clinic has been through this before with other wildfires, COVID-19 has provided another level of complexity to keep everyone safe while still trying to provide response, he said. Before, they could squeeze 20 people in the medical area without a second thought. Now they need to be aware of physically distancing.

But one positive from the pandemic is that the staff is already better versed in telemedicine, so the hospital can be reserved for the most critical cases.

We are able to use FaceTime, Zoom and other platforms to communicate with vets at the evacuation centers, McNabb said. This streamlined medical care were able to provide reduces the stress of hauling and transportation.

Santa Cruz animal shelter moves into next phase

Meanwhile, down on the coast, the Santa Cruz County Animal Shelter moved a majority of its animals out of the shelter on Wednesday night in preparation for evacuations, with 200 pets now in foster care, said general manager Melanie Sobel. Since Thursday morning, a steady flow of dogs and cats has arrived, as well as birds, snakes, geckos, monitor lizards, a frog, a tarantula and two horses. About 400 animals occupy the shelter now.

Sobel said intake has slowed down, and now people are coming in to pick up or drop off donations since many fleeing their homes didnt have time to grab basic supplies. Now the shelter is refocusing efforts.

The next phase were working on is addressing the hundreds of calls for residual pets left by people, such as chickens and outdoor cats, that are not as easy to round up in a panic, Sobel said. Once those areas are clear, were sending teams up there to either help the animals shelter-in-place by providing food and water, or taking them into the shelter.

Some of the worst wildfires in state history have occurred in Northern California in just the past few years. For better or worse, communities are improving response and acting quickly.

The silver lining to come out of past tragedies is everyone is more and more prepared than the last one, McNabb said. The activation of personnel and of resources came together rapidly. Theres been a good job at the local response with local livestock owners, horsemen and volunteers supporting and assisting in working together.

Now, communities are holding their breath, hoping that possible thunderstorms and windy conditions dont worsen the wildfires. If things dont take a turn in the next few days, Salpeter hopes Sweet Farm will have its animals back this weekend, bringing life to the sanctuary once again.

Were staying positive, he said. We have our fingers crossed that the community comes out stronger than before. Even if something did happen, we will get through it.

Kellie Hwang and Nora Mishanec are San Francisco Chronicle staff writers. Email: kellie.hwang@sfchronicle.com, nora.mishanec@hearst.comTwitter: @KellieHwang., @NMishanec

See the original post:
Animals large and small saved by a rescue network forged by years of Bay Area wildfires - San Francisco Chronicle

Read More...

ProgenCell – Stem Cell Therapies announces new facilities – PR Web

August 28th, 2020 2:53 am

Our patients will have access to even more services and extraordinary specialists available at the medical tourism complex, in a convenient and strategic location.

SAN DIEGO (PRWEB) August 25, 2020

ProgenCell - Stem Cell Therapies is announcing the opening of its brand new Stem Cell Treatment Center to give international and local patients a more comprehensive medical treatment in a luxury and stress free environment. With this announcement, ProgenCell establishes its leadership in the field of regenerative medicine and medical tourism. ProgenCells New Clinic is part of the one of a kind all-in-house medical tourism complex: NewCity Medical Plaza.

A great deal of planning went into making this stem cell treatment right for the wide range of medical conditions we deal with, said Dr Jorge Gavino, president of ProgenCell Scientific Committee. Our patients will have access to even more services and extraordinary specialists available at the medical tourism complex, in a convenient and strategic location. Im excited to welcome patients at this new facility.

It has been a long journey. Time had given lot of experience since 2008, when the clinic was found, said Elias Bemaras, CEO. Stem cell therapy has evolved, has improved in many ways, getting better results, learning from long term treated patients. We understand the need for a new facility, more convenient for patients with equipment renovation, better distribution, and a better location. Although a high investment is required, we believe it is worth it because our patients will receive better service, easier logistics, more time with the doctor, better follow up, and that translates to 360 degrees patient satisfaction.

With this new facility, ProgenCell establishes its commitment to offer the most advanced technology in modern and comfortable facilities and in a fully licensed, government regulated and certified facility, overseen by an independent ethics and scientific committee.

About ProgenCell - Stem Cell TherapiesProgenCell - Stem Cell Therapies is a leading stem cell treatmentcenter that offers individualized stem cell therapies for patients with chronic-degenerative diseases with more than 10 years of experience. ProgenCell also provides assistance with lodging, traveling and logistics to provide a comprehensive and safe medical tourism experience.ProgenCell is now part of the Health System of NewCity Medical Plaza, a modern and innovative Medical Tourism Center in Tijuana, Mexico. NewCity Medical Plaza is a 30-story tower, with doctors offices, hospital, medical lab, imaging center, commercial plaza, gastronomic center and a 140-room five star hotel.

To learn more about ProgenCell new facilities or scheduling inquiries contact ProgenCell directly at 1 888 443 6235 or email info@progencell.com

Share article on social media or email:

Go here to see the original:
ProgenCell - Stem Cell Therapies announces new facilities - PR Web

Read More...

LSNE-Len Receives Approval From AEMPS To Manufacture Biotechnology Based Therapeutic Products – PRNewswire

August 28th, 2020 2:52 am

BEDFORD, N.H., Aug. 27, 2020 /PRNewswire/ --LSNE Contract Manufacturing, a leading contract development and manufacturing organization, is pleased to announce that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the manufacturing of clinical stage biotechnology based therapeutic products at its aseptic fill finish facility in Len, Spain. This important approval builds upon LSNE's well-established capabilities in providing aseptic fill finish of biologic products for clients at its US facilities. These products include monoclonal antibodies, fusion proteins, replacement enzymes, plasmids, capsids, and oligonucleotides.

"The authorization of biologic manufacturing for clinical drug product in both vial and pre-filled syringe (PFS) presentations is a vital step to our maturation of drug product manufacturing at our facility in Spain. This will provide the global market with more access to LSNE facilities for the manufacture of these high-value biologics, including monoclonal antibodies and other recombinant proteins," said Shawn Cain, LSNE's Chief Operating Officer.

Jaime Del Campo, Site Head at LSNE-Len said, "We are thrilled with this most recent milestone and our ongoing partnership with AEMPS. This is another big step forward supported by our industry leading quality and operations teams. We anticipate this authorization will have an immediate impact in our ability to support our client's varied clinical programs and ensures long-term benefits to their future commercial supply."

About LSNE

LSNE is a privately held company with six GMP facilities four located in New Hampshire, one in Wisconsin and one located in Len, Spain. LSNE has been providing contract lyophilization services to the pharmaceutical, biotechnology, and medical device industries since 1997, specializing in a wide range of services including process cycle development, fill-finish and lyophilization (for vials, pre-filled syringes and dropper bottles for ophthalmics), and analytical testing. Through the thoughtful integration of six processing facilities, qualified staffing, and extensive manufacturing history, LSNE is strategically positioned to provide products and services for clinical through commercial supply for pharmaceuticals and medical devices to a global market.

Media Contact

Jeff ClementVice President of Business Development(603) 668-5763[emailprotected]www.lyophilization.com

SOURCE LSNE Contract Manufacturing

Home

Read more:
LSNE-Len Receives Approval From AEMPS To Manufacture Biotechnology Based Therapeutic Products - PRNewswire

Read More...

Australia can take the lead in biotechnology revolution | The Strategist – The Strategist

August 28th, 2020 2:52 am

The Australian government needs to develop a bold vision and strategic plan to create the data-driven healthcare system and bioeconomy of the future.

In my new report for ASPI, Biodata and biotechnology: Opportunity and challenges for Australia, I explain how the extraordinary developments in genome sequencing and genetic engineering will transform all biological enterprises, especially healthcare, and create new ones, like the electronic revolution. I explain why Australia should harness and capitalise on our high-quality biomedical science, agricultural research and development, and healthcare systems to realise a once-in-a-generation opportunity to play a leading role in a major economic revolution.

Biotechnology dates back over 6,000years to the domestication of wheat and the use of yeast for fermentation, but has entered the province of human design and invention as a consequence of the gene-cloning, gene-manipulation and genome-sequencing revolutions of the past 50years.

While often thought of in terms of drug development and genetic engineering, biotechnology is fundamentally becoming an information industry with a universe of applications.

Humans have acquired the ability to read the genetic programming and analyse the structure of the molecules of lifehow cells work, how were different from each other, and what makes a lime different from a lemon. Life has evolved the most exquisite nanomachinesprotein machines that can bind oxygen and almost any other type of molecule; trap photons to turn carbon dioxide and water into carbohydrates; detect electric fields or sound waves and turn them into visual images; pump ions; facilitate the entry of viruses, bacteria and parasites into cells; and make molecular motors that spin or contract to trap prey, exert force and move.

The extraordinary advances in DNA sequencing are leading to an avalanche of genomic information. Genetic engineering can now be done with high speed and precision. The pace of change is accelerating, and biological technologies are intersecting with optical technologies, nanotechnologies, advanced computing and artificial intelligence to create possibilities that were, if not beyond imagination, well beyond feasibility just a few years ago.

The advent of population-scale genomic and smart sensor data will transform health care, health economics, medical research and drug development. It will also transform the national economy and create digital products that can be exported to the world. To achieve this, the Australian government needs a strategic plan for acquiring genomic, clinical, pharmaceutical, sensor and patient self-reporting data and for providing trusted online evidence-based analysis of that information and advice to healthcare practitioners and citizens.

Governments also need to convince citizens of the personal and national value of big data in health care, and the privacy and security of that data, using a model that combines political leadership with subject-matter expertise.

The Australian government should establish a secure national repository for genomic and phenotypic data for research and healthcare use. This de-identified data should be made available to Australian researchers and health system managers. It could be provided to external parties, such as pharmaceutical companies, under appropriate conditions in exchange for early access to expensive treatments or shared benefits.

The Australian government should establish a central unit to assemble and supply evidence-based, well-curated and continuously updated genomic analysis, integrated with clinical and other data, and linked to national treatment guidelines, for decision support at the point of care.

The cost of doing this will be trivial compared with other costs in the healthcare system, and trivial in relation to the cost reductions and healthcare improvements that it will enable. This work could be funded from the Medical Research Future Fund and publicprivate partnerships.

Smart sensors should be made available through Medicare and routinely installed in hospitals, clinics and other healthcare settings, such as aged-care homes.

Conversion to electronic health records should be mandatory for all healthcare providers receiving government support or reimbursement in Australia, as recommended by the Australian Academy of Technology and Engineering.

Genetic tests should be progressively upgraded to whole-genome sequencing to build the national genomic estate. That would convert diagnostic expenses into an enduring strategic asset.

All suitably accredited health professionals, including general practitioners, should be able to obtain a genomic report, pharmacogenomic advice, early warning of an incipient disease, or any combination of that information, about a patient (with patient approval) upon request, and bulletins issued where relevant. Citizens should also be entitled to access such information in the interests of caring for their own health, provided it is conservative and actionable.

Security and police agencies should establish internal expertise in biotechnology and biodata analysis. They should have access to national genomic information under defined circumstances and subject to judicial approval and oversight.

Major investment funds and relevant government departments should consider establishing bio-intelligence units to keep abreast of opportunities and incorporate those opportunities into their strategic planning. Australian research funding agencies and the CSIRO should continue to invest in advanced genetic engineering and vaccine and drug development. Superannuation funds should be encouraged to invest at least 1% of their resources into domestic start-up and early-phase high-tech and digital enterprises, especially in health and biotechnologies.

Universities should provide training in computer programming and big-data analysis as a core component of all science and engineering degrees.

Read this article:
Australia can take the lead in biotechnology revolution | The Strategist - The Strategist

Read More...

Should You Buy Trillium Therapeutics Inc (TRIL) in Biotechnology Industry? – InvestorsObserver

August 28th, 2020 2:52 am

Trillium Therapeutics Inc (TRIL) is around the top of the Biotechnology industry according to InvestorsObserver. TRIL received an overall rating of 65, which means that it scores higher than 65 percent of all stocks. Trillium Therapeutics Inc also achieved a score of 80 in the Biotechnology industry, putting it above 80 percent of Biotechnology stocks. Biotechnology is ranked 24 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Trillium Therapeutics Inc (TRIL) stock has fallen -3.11% while the S&P 500 has gained 0.16% as of 3:10 PM on Thursday, Aug 27. TRIL is lower by -$0.32 from the previous closing price of $10.29 on volume of 718,678 shares. Over the past year the S&P 500 has risen 20.64% while TRIL has gained 3337.93%. TRIL earned $2.58 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 3.87.

To screen for more stocks like TRIL click here.

Read more from the original source:
Should You Buy Trillium Therapeutics Inc (TRIL) in Biotechnology Industry? - InvestorsObserver

Read More...

Agricultural Biotechnology Market: Business Opportunities, Current Trends and Industry Analysis by 2020 to 2026 (Based on 2020 COVID-19 Worldwide…

August 28th, 2020 2:52 am

The global Agricultural Biotechnology market focuses on encompassing major statistical evidence for the Agricultural Biotechnology industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Agricultural Biotechnology study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Agricultural Biotechnology industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Agricultural Biotechnology market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Agricultural Biotechnology report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Agricultural Biotechnology market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Agricultural Biotechnology Market report @ https://hongchunresearch.com/request-a-sample/72153

Key players in the global Agricultural Biotechnology market covered in Chapter 4:, Monsanto, KWS SAAT, Certis, Bayer CropScience, DuPont Pioneer Hi-Bred, Evogene, Dow AgroSciences, Syngenta, Mycogen Seeds., Vilmorin

In Chapter 11 and 13.3, on the basis of types, the Agricultural Biotechnology market from 2015 to 2026 is primarily split into:, Molecular Diagnostics, Molecular Markers, Tissue Culture, Vaccines, Genetic Engineering, Others

In Chapter 12 and 13.4, on the basis of applications, the Agricultural Biotechnology market from 2015 to 2026 covers:, Transgenic Crops, Synthetic Biology-Enabled Products, Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Agricultural Biotechnology market study further highlights the segmentation of the Agricultural Biotechnology industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Agricultural Biotechnology report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Agricultural Biotechnology market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Agricultural Biotechnology market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Agricultural Biotechnology industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Agricultural Biotechnology Market Report with [emailprotected]https://hongchunresearch.com/report/agricultural-biotechnology-market-2020-72153

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Agricultural Biotechnology Market

Chapter Four: Players Profiles

Chapter Five: Global Agricultural Biotechnology Market Analysis by Regions

Chapter Six: North America Agricultural Biotechnology Market Analysis by Countries

Chapter Seven: Europe Agricultural Biotechnology Market Analysis by Countries

Chapter Eight: Asia-Pacific Agricultural Biotechnology Market Analysis by Countries

Chapter Nine: Middle East and Africa Agricultural Biotechnology Market Analysis by Countries

Chapter Ten: South America Agricultural Biotechnology Market Analysis by Countries

Chapter Eleven: Global Agricultural Biotechnology Market Segment by Types

Chapter Twelve: Global Agricultural Biotechnology Market Segment by Applications12.1 Global Agricultural Biotechnology Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Agricultural Biotechnology Sales and Market Share by Applications (2015-2020)12.1.2 Global Agricultural Biotechnology Revenue and Market Share by Applications (2015-2020)12.2 Transgenic Crops Sales, Revenue and Growth Rate (2015-2020)12.3 Synthetic Biology-Enabled Products Sales, Revenue and Growth Rate (2015-2020)12.4 Others Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Agricultural Biotechnology Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/72153

List of tablesList of Tables and FiguresTable Global Agricultural Biotechnology Market Size Growth Rate by Type (2020-2026)Figure Global Agricultural Biotechnology Market Share by Type in 2019 & 2026Figure Molecular Diagnostics FeaturesFigure Molecular Markers FeaturesFigure Tissue Culture FeaturesFigure Vaccines FeaturesFigure Genetic Engineering FeaturesFigure Others FeaturesTable Global Agricultural Biotechnology Market Size Growth by Application (2020-2026)Figure Global Agricultural Biotechnology Market Share by Application in 2019 & 2026Figure Transgenic Crops DescriptionFigure Synthetic Biology-Enabled Products DescriptionFigure Others DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Agricultural Biotechnology Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Agricultural Biotechnology Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Agricultural BiotechnologyFigure Production Process of Agricultural BiotechnologyFigure Manufacturing Cost Structure of Agricultural BiotechnologyFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Monsanto ProfileTable Monsanto Production, Value, Price, Gross Margin 2015-2020Table KWS SAAT ProfileTable KWS SAAT Production, Value, Price, Gross Margin 2015-2020Table Certis ProfileTable Certis Production, Value, Price, Gross Margin 2015-2020Table Bayer CropScience ProfileTable Bayer CropScience Production, Value, Price, Gross Margin 2015-2020Table DuPont Pioneer Hi-Bred ProfileTable DuPont Pioneer Hi-Bred Production, Value, Price, Gross Margin 2015-2020Table Evogene ProfileTable Evogene Production, Value, Price, Gross Margin 2015-2020Table Dow AgroSciences ProfileTable Dow AgroSciences Production, Value, Price, Gross Margin 2015-2020Table Syngenta ProfileTable Syngenta Production, Value, Price, Gross Margin 2015-2020Table Mycogen Seeds. ProfileTable Mycogen Seeds. Production, Value, Price, Gross Margin 2015-2020Table Vilmorin ProfileTable Vilmorin Production, Value, Price, Gross Margin 2015-2020Figure Global Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Global Agricultural Biotechnology Revenue ($) and Growth (2015-2020)Table Global Agricultural Biotechnology Sales by Regions (2015-2020)Table Global Agricultural Biotechnology Sales Market Share by Regions (2015-2020)Table Global Agricultural Biotechnology Revenue ($) by Regions (2015-2020)Table Global Agricultural Biotechnology Revenue Market Share by Regions (2015-2020)Table Global Agricultural Biotechnology Revenue Market Share by Regions in 2015Table Global Agricultural Biotechnology Revenue Market Share by Regions in 2019Figure North America Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Europe Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Asia-Pacific Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Middle East and Africa Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure South America Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure North America Agricultural Biotechnology Revenue ($) and Growth (2015-2020)Table North America Agricultural Biotechnology Sales by Countries (2015-2020)Table North America Agricultural Biotechnology Sales Market Share by Countries (2015-2020)Figure North America Agricultural Biotechnology Sales Market Share by Countries in 2015Figure North America Agricultural Biotechnology Sales Market Share by Countries in 2019Table North America Agricultural Biotechnology Revenue ($) by Countries (2015-2020)Table North America Agricultural Biotechnology Revenue Market Share by Countries (2015-2020)Figure North America Agricultural Biotechnology Revenue Market Share by Countries in 2015Figure North America Agricultural Biotechnology Revenue Market Share by Countries in 2019Figure United States Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Canada Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Mexico Agricultural Biotechnology Sales and Growth (2015-2020)Figure Europe Agricultural Biotechnology Revenue ($) Growth (2015-2020)Table Europe Agricultural Biotechnology Sales by Countries (2015-2020)Table Europe Agricultural Biotechnology Sales Market Share by Countries (2015-2020)Figure Europe Agricultural Biotechnology Sales Market Share by Countries in 2015Figure Europe Agricultural Biotechnology Sales Market Share by Countries in 2019Table Europe Agricultural Biotechnology Revenue ($) by Countries (2015-2020)Table Europe Agricultural Biotechnology Revenue Market Share by Countries (2015-2020)Figure Europe Agricultural Biotechnology Revenue Market Share by Countries in 2015Figure Europe Agricultural Biotechnology Revenue Market Share by Countries in 2019Figure Germany Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure UK Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure France Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Italy Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Spain Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Russia Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Asia-Pacific Agricultural Biotechnology Revenue ($) and Growth (2015-2020)Table Asia-Pacific Agricultural Biotechnology Sales by Countries (2015-2020)Table Asia-Pacific Agricultural Biotechnology Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Agricultural Biotechnology Sales Market Share by Countries in 2015Figure Asia-Pacific Agricultural Biotechnology Sales Market Share by Countries in 2019Table Asia-Pacific Agricultural Biotechnology Revenue ($) by Countries (2015-2020)Table Asia-Pacific Agricultural Biotechnology Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Agricultural Biotechnology Revenue Market Share by Countries in 2015Figure Asia-Pacific Agricultural Biotechnology Revenue Market Share by Countries in 2019Figure China Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Japan Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure South Korea Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Australia Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure India Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Southeast Asia Agricultural Biotechnology Sales and Growth Rate (2015-2020)Figure Middle East and Africa Agricultural Biotechnology Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read more:
Agricultural Biotechnology Market: Business Opportunities, Current Trends and Industry Analysis by 2020 to 2026 (Based on 2020 COVID-19 Worldwide...

Read More...

Is TFF Pharmaceuticals Inc (TFFP) The Right Choice in Biotechnology? – InvestorsObserver

August 28th, 2020 2:52 am

A rating of 94 puts TFF Pharmaceuticals Inc (TFFP) near the top of the Biotechnology industry according to InvestorsObserver. TFF Pharmaceuticals Inc's score of 94 means it scores higher than 94% of stocks in the industry. TFF Pharmaceuticals Inc also received an overall rating of 79, putting it above 79% of all stocks. Biotechnology is ranked 24 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

TFF Pharmaceuticals Inc (TFFP) stock is trading at $14.63 as of 11:38 AM on Thursday, Aug 27, a gain of $1.06, or 7.81% from the previous closing price of $13.57. The stock has traded between $13.56 and $15.19 so far today. Volume today is low. So far 451,577 shares have traded compared to average volume of 773,030 shares.

To screen for more stocks like TFFP click here.

Read the original post:
Is TFF Pharmaceuticals Inc (TFFP) The Right Choice in Biotechnology? - InvestorsObserver

Read More...

Should You Buy Miragen Therapeutics Inc (MGEN) in Biotechnology Industry? – InvestorsObserver

August 28th, 2020 2:52 am

Miragen Therapeutics Inc (MGEN) is near the top in its industry group according to InvestorsObserver. MGEN gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Miragen Therapeutics Inc gets a 79 rank in the Biotechnology industry. Biotechnology is number 24 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Miragen Therapeutics Inc (MGEN) stock is trading at $0.99 as of 11:38 AM on Thursday, Aug 27, an increase of $0.03, or 3.11% from the previous closing price of $0.96. The stock has traded between $0.96 and $1.02 so far today. Volume today is low. So far 394,762 shares have traded compared to average volume of 3,432,571 shares.

To see InvestorsObserver's Sentiment Score for Miragen Therapeutics Inc click here.

Read the original here:
Should You Buy Miragen Therapeutics Inc (MGEN) in Biotechnology Industry? - InvestorsObserver

Read More...

Where Does Amarin Corporation plc (AMRN) Stock Fall in the Biotechnology Field? – InvestorsObserver

August 28th, 2020 2:52 am

Amarin Corporation plc (AMRN) is near the bottom in its industry group according to InvestorsObserver. AMRN gets an overall rating of 38. That means it scores higher than 38 percent of stocks. Amarin Corporation plc gets a 28 rank in the Biotechnology industry. Biotechnology is number 24 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 38 would rank higher than 38 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Amarin Corporation plc (AMRN) stock is trading at $7.60 as of 11:39 AM on Thursday, Aug 27, a rise of $0.55, or 7.78% from the previous closing price of $7.05. The stock has traded between $6.95 and $7.78 so far today. Volume today is elevated. So far 6,776,575 shares have traded compared to average volume of 5,392,224 shares.

To see InvestorsObserver's Sentiment Score for Amarin Corporation plc click here.

Read more:
Where Does Amarin Corporation plc (AMRN) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases -…

August 28th, 2020 2:52 am

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Aug. 24, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company today announced that it has entered into a strategic collaboration with Vir Biotechnology (Nasdaq: VIR), a clinical-stage immunology company, to discover, develop and commercialize potential novel therapeutic molecules in the fields of Immuno-Oncology and infectious diseases.

HBM will leverage its tools in next-generation technologies including its transgenic Harbour Mice® platforms to generate antibodies for the collaboration. Both parties will then combine their expertise in basic science to accelerate the development of these innovative immunotherapies into the clinic studies for patients suffering from cancers and infectious diseases.

"We are excited to join hands with Vir as both companies share a common mission to serve patients' unmet needs," said Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed. "This collaborative partnership harbors big potential for both companies, as we exploit similar underlying immune mechanisms that likely play a critical role in fighting cancers as well as infectious diseases."

About Harbour BioMed

Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19. The company is building its proprietary pipeline through internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

The company's internal discovery programs are centered around its two patented transgenic mouse platforms (Harbour Mice®) for generating both fully human monoclonal antibodies, heavy chain only antibodies (HCAb) and HBICE immune cell engager technology for developing bispecific antibodies. Harbour BioMed also licenses the platforms to companies and academic institutions. The company has operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Suzhou & Shanghai, China. For more information, please visit http://www.harbourbiomed.com

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.

View original content to download multimedia:http://www.prnewswire.com/news-releases/harbour-biomed-signs-strategic-collaboration-agreement-with-vir-biotechnology-to-develop-novel-therapies-for-immuno-oncology-and-infectious-diseases-301116941.html

SOURCE Harbour BioMed

Continued here:
Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases -...

Read More...

FDA Clears Jointechlabs’ MiniTC for Point-of-Care Fat Tissue Processing and its Broad Range of Applications – PRNewswire

August 26th, 2020 3:54 pm

SAN FRANCISCO, Aug. 26, 2020 /PRNewswire/ --Jointechlabs a leader in point-of-care regenerative medicine therapies today announced that the U.S. Food and Drug Administration (FDA) cleared the company's MiniTCfor point-of-care fat tissue processing designed to obtain microfat (or fat grafts), for multiple indications. Jointechlabs plans to focus on a range of therapeutic areas including medical aesthetics, plastic surgery, orthobiologics and wound healing.

"The FDA clearance of MiniTC represents an important step forward in the regenerative medicine market," said Nathan Katz, Jointechlabs' CEO. "The company's comprehensive and proprietary technology provides a variety of tissue reconstruction and regeneration options, enabling healthcare practitioners in medical centers, hospitals and clinics to provide safe, reliable and cost-effective cell enriched fat grafts at the point-of-care."

MiniTC is a disposable, closed loop medical device that can be used in the clinic setting, with no change in infrastructure, eliminating the need for manual processing of fat tissue in the lab. Also, the device is less costly,cumbersome and labor intensive compared to what currently exists. MiniTC's performance has been validated in vitro and in vivo, including an observational orthopedic study in Israel and the UAE, involving 47 patients with 92% reporting functional improvement and no complications. Additionally, it was validated in clinical studies with lymphoedema patients as well as in the areas of facial aesthetics, hair regrowth and wound care.

"Jointechlabs' MiniTC device is easy to use and effective," said Joseph Purita, M.D., orthopedic surgeon and director of the Institute of Regenerative Medicine in Boca Raton, Florida."It is encouraging to see the continuing development of new technology for regenerative medicine that is compliant with FDA guidelines."

Microfat IsolationMiniTC allows for processing of adipose (fat) tissue without exposure to the external environment. The final product of the processing is a fine washed fractured fat tissue known as fat graft or microfat. When implanted by injection, the essential effect can be attributed to the preservation of the integrity of fat tissue and the stromal cells within its natural niche. Together it constitutes structural factors that trigger the reconstruction, regeneration and healing of connective tissues.It's a gentle process that uses an individual's own fat tissue tocushion and support areas of injury or damage as the body heals itself.

Pipeline ProductsJointechlabs has an extensive development program. In addition to MiniTC, the company's Mini-Stem a patented, disposable, closed loop medical device is pending approval in Europe (and under investigation in other countries) for isolation of stem cell fraction (SVF) from fat. Mini-Stem will enable doctors to provide safe, reliable, cost-effective non-surgical stem cell treatments at the point-of-care. Mini-Stem will serve as a platform for cell therapies and is well poised to target the developing regenerative medicine market, unlike any of the current devices.Additionally, Jointechlabs is developing proprietary stem cell-scaffold product as a biologic therapy for osteoarthritis, for approval under the FDA's fast-track program. A portion of the pre-clinical study for JTL-T-01 is funded by NIH's small business grant (SBIR grant) in collaboration with Rush University.

Headquartered in San Francisco, Jointechlabs is recognized as an experienced and respected emerging world leader in point-of-care regenerative medicine therapies. With its devices and technology, Jointechlabs enables healthcare practitioners to provide safe, reliable, cost-effective non-surgical regenerative medicine treatments at the point-of-care.For more information, please visit: http://jointechlabs.com/.

Media Contact:Betsy Levy | Phone: (415) 377-3112 | Email: [emailprotected]

SOURCE Jointechlabs

Home

Here is the original post:
FDA Clears Jointechlabs' MiniTC for Point-of-Care Fat Tissue Processing and its Broad Range of Applications - PRNewswire

Read More...

Photos That Reveal the Hidden Side of Things – Obsev

August 26th, 2020 3:54 pm

The world is full of wondrous things, but sometimes it's easy to forget this because were always so busy and stressed out.

Well, as luck would have it, there are some beautiful secrets hidden in plain sight and inside of things that most of us would never think to look at twice. So heres a collection of the hidden side of things that youve totally missed.

A ghost heart is created when doctors wash away all the donor cells. What you see here is a protein scaffold. This means the ghost heart is ready to receive a transplant of the recipients stem cells so that a new non-rejecting heart can be grown.

This might be hard to believe, but this is a human embryo in its early stages of development. Its actually sitting on the tip of a needle. Who would have imagined that we all looked this tiny at some point?

It might look like a bunch of fiber-optic cables, but this isnt the inside of a computer or a vast computer network. Its actually the inside of a tire and those cables are actually tire spokes.

The Easter Island Heads were carved from stone by ancient Polynesians somewhere between 1100 AD and 1500 AD. Most people only get to see these giant heads. However, they also have bodies that are buried underneath the surface.

Have you ever wondered what a blue whales blowhole actually looks like? Well here it is. And the funny thing is that it looks like a giant human nose or the nose of a statue floating on its back.

Most people assume that flamingos are tall and pink their entire lives, but thats not the case. A flamingos parent feeds them a bright red milk developed from their digestive tracts. As the baby continues to grow, it starts to develop pink feathers. And as adults, flamingos feed on a red and blue-green algae filled with beta carotene and an organic chemical with a reddish-orange pigment. Their digestive tracts extract the pigment which dissolve into fat. This fat is then deposited into new feathers, hence their pink color.

Have you ever wondered what the underside of a Lilly Pad looks like? Well it looks an awful lot like a placenta or a really veiny bathroom mat. Actually, it does function a bit like a placenta, taking nutrients to where they are needed.

This intricate network is a real human nervous system. In 1926, two medical students named M.A. Schalck and L.P. Ramsdell from Kirksville, Missouri, dissected a cadavers nervous system. The entire process took over 1,500 hours.

Most people assume that a turtles shell is just a shell. But it turns out that its a huge part of their skeletal structure. In fact, you might say its almost like an exo-skeleton and theres plenty of room for organs on the inside.

This is what salt crystals look like under an electron microscope. Some grains appear to be cubical while others are made up of overlapping cubes. The ionic compound of these salt crystals is composed of sodium and chloride atoms. When these molecules come together to form a crystal, they often arrange themselves in a cubical pattern.

If you thought brick streets were laid on the ground a brick at a time by underpaid laborers, guess again. In this photo, workers use a machine to lay an entire layer of bricks on this street in the Netherlands.

This ice crystal was found in Switzerland and it turns out that these crystals vary in intensity, shape and size. Scientists believe that these ice crystals grow to precipitation size because of a culmination of smaller ice crystals.

At a glance, this looks like the interior cabin of a boat or a really fancy apartment that most of us could never afford. But what youre really looking at is the inside of a really nice guitar that most of us probably couldnt afford either.

You know how everyones always telling you to wash your hands? You should listen to them. These are microbes left behind from an 8-year-old boys handprint after playing outside. Fortunately, your immune system will fight off most infectious agents.

Auroras are cosmic lights that can be seen from different planets in our solar system. They occur when the sun emits a stream of charged particles into the solar system. When the solar winds hit a planet, they interact with the surrounding magnetic field and compress the field into a teardrop type shape. This collision between nitrogen and oxygen molecules releases an energy that looks a lot like light ribbons across the sky.

This photo was taken by NASA of one of their space shuttles leaving Earths atmosphere. But to the untrained eye, it looks more like a hot needle poking through wool. It also looks like the shuttle is dragging some of the clouds up into space.

Most people assume that a tigers stripe is produced by patterns in their fur. But it turns out that their skin is also patterned. The darkness of the pigmentation of the skin is directly linked to the furs darkness.

Most people know what cacti look like, so its so surprising that this photo has any connections to one but it does. This is actually what remains of a dead cactus after it decomposes. All thats left are thorny spines that are sharp as knives.

You dont need x-ray vision to look inside a glass frog. This interesting species lives in the rain forests of Costa Rica, Ecuador, Colombia and Panama. And the skin on their underside is fully transparent, so you can literally see their beating heart and other internal organs.

This is what an elephant tail looks like up close and personal. Elephants use it to communicate with other elephants by wagging or swishing their tail. They also use their tail as a flyswatter to keep mosquitoes and flies from biting them.

What youre seeing is an agate shell thats been cut in half. Over time, minerals grew into the empty crevices and they eventually replaced the shell, too. So basically, it underwent a beautiful mineral metamorphosis.

Believe it or not, this isnt some futuristic set from a Sci-Fi movie or the interior of an alien spaceship docked in Area 51. Its an empty Boeing 787. The only difference here is that all of the seats have been removed from the cabin.

When we hear the word raccoon, most of us imagine that black and white look that reminds us of a burglar. But this raccoon suffers from a congenital disorder called Albinism, which has caused a complete loss of pigmentation. And since these creatures dont have their natural camouflage, theyre more vulnerable to attacks from predators.

Reporters out on the field always look so fabulous, but no one really shows you whats going on behind the scenes, or in this case, their backs. In reality, journalists have to wear transmitters, cables, and clip-on microphones that make them look like cyborgs.

When you think of a starfish, you imagine that it will be shaped like a star. But due to a rare birth defect, some 5-pointed starfish come out looking square-shaped. But while they might look different, their intricate patterns are still beautiful.

Go here to read the rest:
Photos That Reveal the Hidden Side of Things - Obsev

Read More...

FINNCAP’S LIFE SCIENCES REPORT INDICATES CELL AND GENE THERAPY SECTOR IS DRIVING THE NEXT WAVE OF INNOVATION IN PHARMA – PharmiWeb.com

August 26th, 2020 3:53 pm

Breakthrough in delivery for cell and gene therapy products has led to a wave of M&A activity as big pharma aims not to miss out on the future of medicine

AIM healthcare index at the centre of innovation, has risen 6% YTD compared with the AIM all share, which has declined 7%

finnLife 50 index has also risen 6% in 2020 led by gains in Synairgen (+2,930%), Avacta (+654%), Omega Diagnostics (+322%) and Tiziana Life Sciences (+283%)

London 25 August 2020 Healthcare companies employing and developing cell and gene therapy (C>) are driving the next wave of innovation in the pharmaceutical industry, leading to increased M&A activity as big pharma aims not to miss out on the future of medicine. The AIM healthcare index has been at the centre of this innovation, rising 6% YTD compared with the AIM all share, which has declined 7%.

These are the findings of finnCaps new quarterly Life Sciences sector report, Rude Health.

Rather than just treating a disease and its symptoms, C> can target the underlying cause of a disease, with long-term benefits and curative potential. C> is now being realised on an applicable level, with many products already approved and the FDA expects to approve 10-20 products a year by 2025.

The financials of the sector are reflective of this rapid progress. In 2018, the market value of C> was $536 million - $1.07 billion; but by 2026 it is set to have a valuation of up to$35.4 billion. Given the high proportion of start-ups in the sector, M&A activity is on the rise, as evidenced by the $3 billion Astellas spent in January 2020 to acquire Audentes Therapeutics, specialists in genetics medicines.

In 2014/2015, M&A activity in the sector was $5 billion; by 2018/2019 it had surged 880% to $49 billion. Much of this is driven by big pharma firms not wanting to fall behind their smaller, more versatile competition, as they did with monoclonal antibody technology. Consequently, they have engaged with M&A to speed up and enhance their own R&D efforts.

The report notes that innovators in C> will be well placed to take part in the land grab that will follow as a result of continued advancements in the sector, and highlights now as a good time for investors and pharmaceutical companies to become involved as the sector is rapidly maturing past its high potential research and development stage with an established pipeline of therapies already being developed.

Some of the key reasons why the report considers the C> sector to be an attractive one for investment are:

Pharmas next wave of innovation. C>s can be potentially curative treatment options as they usually target the underlying cause of disease. In the long term, these therapies could become the backbone of treatment regimens, and solutions to various unmet needs.

Deals. Big Pharma had to play catch-up with monoclonal antibody technology and seems determined not to make the same mistake with C>, as reflected in the high deal activity and high deal values seen within this space.

Sector maturation. Advances in the sector mean that the C> sector is beginning to mature beyond the R&D stage and into commercialisation, with some products already approved, and with a very large future pipeline of therapies.

Revenue.Therapies in this space can command high prices, allowing for high revenue generation, even from rare diseases and limited patient populations.

Despite its vital role in the future of medicine, C> also comes with challenges. The report highlights that the manufacture of C>s is difficult given they are, by definition, personalised for the patient. This means they cannot be batch produced for distribution to multiple patients as more traditional medicines can. For example, Zolgensma, which treats those with motor neurone disease, is priced at $2.1 (1.6) million per therapy, making it the most expensive drug treatment ever.

The report also notes how the payment process for C> requires a reworking of reimbursement systems not used to outlaying so much money up front for a treatment with long-term benefits/curative potential versus continuous, and lower payments for ongoing medicine treatment.

The technologies the report shines a spotlight include CAR-T therapy, stem cell therapy, CRISPR, RNA therapies, among various others.

Arshad Ahad, Research Analyst, Life Sciences, at finnCap, commented:Few technologies in the life sciences sector hold as much promise as Cell and Gene Therapy, with its ability to provide long-term benefits and curative potential. These technologies have been seen as the future of medicine for many years, and now we are closer than ever to that future becoming a reality. If Cell and Gene therapy does become the backbone of treatment regimes in the future, similar to the rise of monoclonal antibodies, then the companies involved are developing expertise in a critical part of the life sciences industry, which should confer a significant competitive advantage as the sector matures further. Now is therefore a good time to invest in the future.

See more here:
FINNCAP'S LIFE SCIENCES REPORT INDICATES CELL AND GENE THERAPY SECTOR IS DRIVING THE NEXT WAVE OF INNOVATION IN PHARMA - PharmiWeb.com

Read More...

FinnCap touts cell and gene therapy as next wave of innovation in pharma industry – Proactive Investors UK

August 26th, 2020 3:53 pm

The broker said the market value of the sector is expected to increase to up to US$35.4bn by 2026 from its 2018 value of between US$536mln-US$1.07bn

FinnCap Group PLC () has said healthcare companies employing and developing cell and gene therapy (C>) are driving the next wave of innovation in the pharmaceutical industry, which in turn is causing an uptick in mergers & acquisitions as pharma giants aim to be at the forefront of the next development in medicine.

In a report released on Tuesday, the brokerage firm highlighted that the trend was personified in the AIM healthcare index, which has risen 6% in the year to date as opposed to a 7% decline for the AIM All-Share index.

Small caps involved in the sector that have seen rapid share price rises this year such as (), () and (), have also led gains in finnCaps own finnLife 50 index.

The group also reported that the market value of the C> sector is expected to increase to up to US$35.4bn by 2026 from its 2018 value of between US$536mln-US$1.07bn.

M&A is also on the rise given the high number of startups in the sector, finnCap said, with acquisition activity valued at US$49bn in 2018/19 compared to US$5bn in 2014/15.

Much of this is driven by big pharma firms not wanting to fall behind their smaller, more versatile competition, as they did with monoclonal antibody technology. Consequently, they have engaged with M&A to speed up and enhance their own [research & development] efforts, the broker said.

Rather than just treating a disease and its symptoms, C> can target the underlying cause of a disease, with long-term benefits and curative potential. C> is now being realised on an applicable level, with many products already approved and the [US Food & Drug Administration] expects to approve 10-20 products a year by 2025, they added.

As a result, the report said that now was the time for investors to get involved as the C> sector is rapidly maturing past its high potential research and development stage with an established pipeline of therapies already being developed.

However, finnCap cautioned that there were challenges facing the sector including difficulty in manufacturing the therapies due to their personalised nature as well as a potential reworking of reimbursement systems that are not used to outlaying so much money up front for a treatment with long-term benefits/curative potential versus continuous, and lower payments for ongoing medicine treatment.

Few technologies in the life sciences sector hold as much promise as Cell and Gene Therapy, with its ability to provide long-term benefits and curative potential, said finnCap life sciences analyst Arshad Ahad.

These technologies have been seen as the future of medicine for many years, and now we are closer than ever to that future becoming a reality. If Cell and Gene therapy does become the backbone of treatment regimes in the future, similar to the rise of monoclonal antibodies, then the companies involved are developing expertise in a critical part of the life sciences industry, which should confer a significant competitive advantage as the sector matures further. Now is therefore a good time to invest in the future, the research analyst added.

FinnCap shares were steady at 23p in late-morning trading on Wednesday.

See the rest here:
FinnCap touts cell and gene therapy as next wave of innovation in pharma industry - Proactive Investors UK

Read More...

Apic Bio Announces Appointment of Jorge A. Quiroz, MD, MBA, as Executive Vice President and Chief Medical Officer – Business Wire

August 26th, 2020 3:53 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apic Bio Inc., a gene therapy company developing novel treatment options for patients with rare genetic diseases, today announced the appointment of Jorge A. Quiroz, MD, MBA, as Executive Vice President, Chief Medical Officer. Dr. Quiroz brings over 20 years of scientific, clinical, and regulatory experience helping to develop and evolve gene therapies and small molecule drug programs from preclinical to regulatory filing. Most recently, Dr. Quiroz served as Chief Medical Officer of Solid Biosciences where he was responsible for leading the clinical advancement of its gene therapy program.

We are excited to welcome Jorge to Apic during this critical period for the company and our pipeline. His extensive expertise in the clinical and regulatory development of gene therapies for rare diseases will support the advancement of both our SOD1 amyotrophic lateral sclerosis (ALS) and alpha-1 antitrypsin deficiency (Alpha-1) programs, said John Reilly, MS, MBA, Co-founder and Chief Executive Officer of Apic. As CMO, Jorge will also lead the development and build out of our early-stage gene therapy programs derived from our THRIVE platform. We look forward to working with Jorge during this next chapter for Apic as we rapidly advance our therapies into the clinic on behalf of patients and families in need.

I am delighted to join Apic during an exciting period of expansion as we prepare to submit an Investigational New Drug (IND) application for APB-102 for the treatment of patients with SOD1 ALS this year and enter the IND-enabling stage for APB-101 for the treatment of patients with alpha-1 antitrypsin deficiency, said Dr. Jorge Quiroz, EVP and Chief Medical Officer of Apic. The Companys mission, deep scientific foundation, clinical approach, and manufacturing expertise puts us in an excellent position to bring new gene therapy treatments to patients living with rare and monogenic disorders.

Dr. Quiroz previously served as the Head of Neurodevelopment & Psychiatry, Translational Medicine Neurosciences at F. Hoffmann-La Roche AG. He has also served as a Director at Johnson & Johnson Pharmaceutical Research & Development, LLC. He received an MD from the Pontifical Catholic University of Chile and completed his medical training as a Research Fellow at the Laboratory of Molecular Pathophysiology, at the National Institute of Mental Health. Dr. Quiroz is board certified in Psychiatry and also holds an MBA dual degree from Columbia University and London Business School.

About Apic Bio

Apic Bio is a gene therapy company focused on developing novel treatment options for rare, undertreated neurological and liver diseases. The Company's lead program is an adeno-associated (AAV)-based gene therapy for the treatment of the copper zinc superoxide dismutase 1 (SOD1) ALS, a genetic form of the disease. Preclinical studies of additional genetic forms of ALS (C9Orf72) and alpha-1 antitrypsin deficiency (Alpha-1) are ongoing. The Company is also advancing discovery programs for two undisclosed CNS indications that leverage its proprietary silence and replace THRIVE platform. The Company is backed by leading and disease-centric investors, including Morningside Ventures, ALS Investment Fund, and The Alpha-1 Project (TAP). For more information please visit http://www.apic-bio.com.

More:
Apic Bio Announces Appointment of Jorge A. Quiroz, MD, MBA, as Executive Vice President and Chief Medical Officer - Business Wire

Read More...

Cryoport strikes second acquisition in a week – Bioprocess Insider – BioProcess Insider

August 26th, 2020 3:53 pm

The addition of cryogenic freezer systems firm MVE Biological Solutions will boost Cryoports position in the temperature-controlled cell and gene therapy logistics space.

Cryoport, a temperature-controlled supply chain services firm for the life sciences, has agree to buy MVE Biological Systems for $320 million with the deal expected to close by the end of the year.

MVE is a subsidiary of Chart Industries and will bring Cryoport a greater presence in the cell and gene therapy services space, broadening its portfolio to include manufactured vacuum insulated products and cryogenic freezer systems. The firm has three manufacturing sites two in the US and one in China and more than 300 customers, including Cryoport itself.

Image: iStock/Zhanna Hapanovich

According to Jefferies analyst Brandon Couillard, MVE has an estimated 55% share of the vacuum insulated products and cryogenic equipment market and the acquisition will bolster Cryoports strategy of becoming the top life sciences supply chain solutions provider, further augmenting its exposure to the rapidly growing cell & gene therapy space.

The deal comes days after Cryoport announced it is buying French logistics firm CRYOPDP for 49 million ($58 million).

Cryoport has fundamentally transformed the company via the CRYOPDP and MVE deals, Couillard said in a note, adding the acquisition spree solidifies Cryoports status as one of the best ways to play the coming cell and gene therapy boom.

Speaking on the deal, Jerrell Shelton, CEO of Cryoport, said: The acquisition of MVE Biological Solutions represents an important step in carrying out Cryoports mission. It further entrenches us in the cell and gene therapy supply chain ecosystem at a time when cell and gene therapies are experiencing rapid and sustained growth, and with an even more exciting growth story ahead.

He added: Bringing MVE Biological Solutions under the Cryoport umbrella, which will include Cryoport Systems, Cryogene, and the recently announced agreement to acquire CRYOPDP is expected to increase our revenue run rate to over$160 millionand to be immediately accretive.

Read the original post:
Cryoport strikes second acquisition in a week - Bioprocess Insider - BioProcess Insider

Read More...

Sunway University’s Collaboration with Harvard Medical School Makes Advances in Potential Cancer Treatment using Gene Therapy – Yahoo Finance

August 26th, 2020 3:53 pm

KUALA LUMPUR, Malaysia, Aug. 26, 2020 /PRNewswire/ --Sunway University's Professor Jeff Tan Kuan Onn of the Department of Biological Sciences and Professor Poh Chit Laa from the Centre for Virus and Vaccine Research, along with their research collaborators from Harvard Medical School's Center for Stem Cell Therapeutics and Imaging (USA) as well as University of Tennessee Health Science Centre (USA) have completed a study that has demonstrated the efficacy of molecular gene therapy as a new strategy for cancer treatment.

Professor Jeff Tan Kuan Onn

The research could potentially contribute to shorter treatment time for cancers, reduce treatment costs and minimise the adverse effects of current chemo-drugs in cancer patients such as susceptibilities toward microbial infections, hair-loss and other side effects of chemo-drugs that drastically affect the quality of life of cancer patients undergoing therapy.

Principal Investigator Professor Jeff Tan explained, "Currently, chemo-drugs are relatively ineffective against cancer cells that have developed drug-resistance resulting in the need for high doses of chemo-drugs or a combination of chemo-drugs to be administered to patients with cancer cells. Chemo-drug resistant cancer cells also can spread quickly and that drastically reduce the survival rate of cancer patients".

"Our research utilises molecular gene therapy which is the introduction of genetic materials into cancer cells to promote the sensitivity of cancer cells to chemo-drugs. By genetically engineering the cancer cells, we find that we can induce the cancer cells to produce activated pro-death and tumour suppressor proteins that cause cell death and growth arrests in cancer cells. The weakened cancer cells can then be killed relatively easily by the administration of chemo-drugs in smaller doses. Ultimately, the research could contribute to increasing the survival rates of cancer patients undergoing cancer treatments," he added.

Co-Investigator Professor Poh Chit Laa said that the effectiveness of the strategy has been demonstrated in mice implanted with human breast cancer cells. "In the mice that weretreated with the gene therapy, the tumours obtained from the treated mice showed significant tumour cell death and the tumours were 20 times smaller and 32 times lighter in volume and weight, respectively, when compared to the tumours obtained from the untreated mice. The results indicated that the gene therapy was able to shrink the tumours significantly, even without treatment with chemo-drugs. Small doses of market-available anti-cancer drugs could then be used to kill the cancer cells effectively. We hope to see our research contribute to better survival rates of cancer patients, and minimise the side-affects associated with anti-cancer drugs," said Professor Poh.

"We are currently working on investigations to optimise the delivery of the gene therapy and anti-cancer drugs to human tumours with hopes that this will result in tangible clinical outcomes," said Professor Jeff Tan.

The research project was recently published in the peer-review Journal of Cancer Research and Clinical Oncology. Collaborators for the research include Lee Yong Hoi, Pang Siew Wai and Samson Eugin Simon from the Department of Biological Sciences, Sunway University; Esther Revai Lechtich and Khalid Shah, of the Center for Stem Cell Therapeutics and Imaging, Brigham and Women's Hospital, Harvard Medical School (USA); Suriyan Ponnusamy and Ramesh Narayanan from the Department of Medicine, Centre of Cancer Drug Discovery, College of Medicine, University of Tennessee Health Science Centre (USA).

Story continues

The research is a result of a collaboration agreement between Harvard Medical School and Sunway University aimed at developing new cancer therapies targeting drug resistant cancer cells. In 2016, Professor Jeff Tan visited Harvard University on the Jeffrey Cheah Travel Grant which enabled him to better understand how cancer research projects are conducted as well as examining experimental models used to study cancer biology at Harvard University, Massachusetts General Hospital (MGH), a hospital affiliated with Harvard Medical School, and the Dana-Farber Cancer Institute.

To read the jointly published article: https://link.springer.com/article/10.1007/s00432-020-03231-9

Photo - https://photos.prnasia.com/prnh/20200825/2898392-1

SOURCE Sunway University

Visit link:
Sunway University's Collaboration with Harvard Medical School Makes Advances in Potential Cancer Treatment using Gene Therapy - Yahoo Finance

Read More...

5 Biotech Stocks That Could Be Worth a Look After an Analyst Started Coverage – Barron’s

August 26th, 2020 3:53 pm

Text size

Newly-hired analyst Danielle Brill launched coverage at Raymond James this week with a 490-page survey of her favorite biotech stocks. Atop the list are hematology drugmaker Acceleron Pharma and the gene therapy developer uniQure.

Brill thinks Acceleron (ticker: XLRN) could rise at least 60%, while uniQure (QURE) could nearly double. Shes also partial to the neurology stock Acadia Pharmaceuticals (ACAD), the hematology stock Global Blood Therapeutics (GBT), and Sarepta Therapeutics (SRPT).

Acceleron has two potential blockbusters, writes Brill in her Monday report. In partnership with Bristol Myers Squibb (BMY), the company recently launched sales of an anemia drug Reblozyl. An investigational drug called sotatercept did well in Phase 2 trials for pulmonary arterial hypertension, a serious congenital disease that can require lung transplants.

After its November 2019 launch, sales of Reblozyl rose to $55 million in the June 2020 quarter as a treatment for beta thalassemia and for a particular type of blood cancer. Brill thinks that the drugs annual sales could exceed $3 billion by the end of the decade, yielding annual royalties of over $750 million for Acceleron. As for sotatercept, she thinks its annual sales could hit $2 billion.

So Raymond James rates Acceleron a Strong Buy, and Brill believes its $92 stock could hit $155.

She also has a Strong Buy on uniQure, saying that its stock could rise more than 90% from its recent price of $39, to at least $75. The shares sold off this year after uniQure licensed its investigational treatment for a kind of hemophilia at a price some investors thought was too low. But Brill thinks the deal made commercial sense and gave uniQure cash to advance its just-started clinical trials of a gene therapy for the deadly neurological disorder Huntingtons disease, which killed songwriter Woody Guthrie, among others.

The first couple of Huntingtons patients were dosed with the gene therapy in June and suffered no safety problems. Brill expects uniQure to have efficacy data in 2021. If the Huntingtons gene therapy succeeds, she predicts a $7 billion annual market for uniQure.

Acadia Pharmaceuticals gets an Outperform rating from Brill. The stock sank from $57 to its current level of $38, after the June news that Acadias drug Nuplazid failed a pivotal trial as a treatment for depression. Nuplazid is already approved as a treatment for psychosis from Parkinsons disease and it allowed Acadia to have 2019 revenue of $340 million, with a loss of $235 million, or $1.60 a share.

By April of next year, the U.S. Food and Drug Administration will decide whether to approve Nuplazid for the large market of dementia patients who suffer psychosis. If approved, the added sales could ultimately exceed $3 billion a year, predicts Brill, while bringing Acadia to profitability by 2022. Good news on Nuplazid would lift Acadia stock to her target of $65.

Global Blood is one of a number of companies bringing long-overdue treatments to the blood disorder known as sickle cell disease. Brill rates its stock an Outperform. In December 2019, the company launched the drug Oxbryta and sales have taken off nicely. If the drugs adoption continues, Brill predicts that it could accrue more than 30,000 patients worldwide, brining annual sales close to $2 billion. That would bring in more than $9 a share in earnings by 2025, she says, and merits her price target of $115 for Global Bloods stock, which currently goes for $64.

Another Outperform rating goes to Sarepta Therapeutics, which aims to add a gene therapy to its approved treatments for Duchenne muscular dystrophy. Data on the gene therapys Phase 2 study will come out in the first quarter of 2021. Brill is optimistic, based on improvements seen in the three of the four patients treated in the Phase 1 trial. The stock market reaction to next years Phase 2 results will be dramatic, she predicts, sending Sarepta shares up or down by $100. Shes a believer and has a $200 price target on the $149 stock.

Write to Bill Alpert at william.alpert@barrons.com

Go here to see the original:
5 Biotech Stocks That Could Be Worth a Look After an Analyst Started Coverage - Barron's

Read More...

Mens Club talks about number one cause of blindness in those over 65 – New Canaan Advertiser

August 26th, 2020 3:52 pm

Published 11:30am EDT, Monday, August 24, 2020

Photo: New Canaan Mens Club / Contributed Photo

Mens Club talks about number one cause of blindness in those over 65

The New Canaan Mens Club will learn about the signs of age-related macular degeneration (AMD), the number one cause of blindness in people over 65, its causes and steps individuals can take to reduce their risk of developing the condition at the clubs virtual meeting Friday, Aug. 28.

In her meeting remarks, by Dr. Cynthia MacKay, a clinical professor of ophthalmology at Columbia University College of Surgeons and Physicians, will describe the risks and symptoms, the two different types of age-related macular degeneration, defined as wet and dry, current treatments and the outlooks for promising future treatments of the condition. Dr. MacKays talk will begin after the clubs business meeting starts at 10 a.m. Shell conclude her remarks with suggestions for how members can decrease their risk of developing AMD.

A board-certified ophthalmologist, Dr. MacKay has comprehensive training in all aspects of eye care, with special training in diseases of the retina and in eye laser surgery.

She received her B.A. from Harvard University and studied medicine at the State University of New York Downstate Health Sciences Center, followed by internship at Lenox Hill Hospital. She did her residency in Ophthalmology at New York Presbyterian Hospital/Columbia University Medical Center.

The New Canaan Mens Club meets virtually in weekly sessions that feature a business meeting, followed by a speaker on a variety of topics. Interested individuals 55-years-old and above may contact the club for more information at ncmens@ncmens.club.

View post:
Mens Club talks about number one cause of blindness in those over 65 - New Canaan Advertiser

Read More...

Excessive computer use could lead to blindness in the future – KGBT-TV

August 26th, 2020 3:52 pm

Now more than ever, people are spending more time in front of a screen.

Its not just adults but kids are also using computers more with online school the norm for the time being.

I never would of thought Id be wearing glasses, Ive never worn glasses, said Linda Medina-Lopez who works remotely.

Medina-Lopez spends more than half the day on her computer.

Gosh if you combine my work time and my pleasure time youre looking at 13-14 hours a day, she said.

It wasnt until recently that she started noticing an increase in headaches and blurry vision that she decided to get blue light glasses.

I went to get checked out with the optometrist and she told me we needed to start blocking some of that blue light and it was going to help with my eye strain. Now its not as blurry, Im very intentional about giving my eyes a break, she explained.

To relieve eye strain, Optometrist Sanda Flores at Pea Institute recommends taking breaks away from your screen throughout the day.

The 20-20-20 rule every 20 minutes taking a 20-second break to look at something 20 feet away so a kid on their computer doing their homework can look at a clock across the room and that can help decrease the fatigue and dryness, Flores said.

Experts say blue light tricks the brain into thinking its daytime, creating sleeping problems and excessive exposure can lead to blindness in the future.Flores recommends setting your phone to night mode to reduce the risk.

They recommend to not do anything on your near device as youre winding down to go to sleep because it can keep your mind a little more alert and make it harder to go to sleep, Flores explained.

Flores also said the brightness on your phone should always match your rooms lighting.

Link:
Excessive computer use could lead to blindness in the future - KGBT-TV

Read More...

Page 408«..1020..407408409410..420430..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick